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Abstract
Background: Azithromycin prophylaxis has been shown to reduce COPD exacerbations but there is poor evidence
for other antibiotics. We compared exacerbation rates in COPD patients with a history of frequent exacerbations
(at least three moderate or severe COPD exacerbations in the past two years) during a 12-week treatment course
and over a subsequent 48-week follow up period.
Results: 292 patients were randomised to one of three treatments for 12 weeks: roxithromycin 300 mg daily and
doxycycline 100 mg daily (n = 101); roxithromycin 300 mg daily (n = 97); or matching placebos (n = 94). There were
no differences in the annualised moderate and severe exacerbation rates after treatment with roxithromycin/
doxycycline (2.83 (95 % CI 2.37-3.40)) or roxithromycin only (2.69 (2.26-3.21)) compared to placebo (2.5 (2.08-3.03))
(p = 0.352 and p = 0.5832 respectively). Furthermore, there were no differences in the annualised exacerbation
rates during 12-week treatment with roxithromycin/doxycycline (1.64 (95 % CI 1.17-2.30)), roxithromycin only
(1.75 (1.24-2.41)) or placebo (2.23 (1.68-3.03)) (p = 0.1709 and p = 0.2545 respectively). There were also no
significant differences between groups for spirometry or quality of life scores over either the 12-week treatment
or 48-week post-treatment periods. Both active treatments were associated with nausea but otherwise adverse
events were comparable among treatment groups.
Conclusions: Twelve-weeks of prophylaxis with roxithromycin/doxycycline combination or roxithromycin alone
did not reduce COPD exacerbations in patients with history of frequent exacerbations. These findings do not
support the use of these antibiotics to prevent exacerbations in COPD patients.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTRN 12615000052538). Date of first
registration: 22 January 2015.
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Background
Acute exacerbations of chronic obstructive pulmonary
disease (COPD) have a major impact on quality of life
and are considered to be a cause of lung function de-
cline [1]. The use of prophylactic antibiotics to reduce
exacerbations rates has had a long history with clinical
trials dating back to the 1950s. However a 2003 meta-
analysis of clinical trials of prophylactic antibiotics in
chronic bronchitis found no significant reduction in the
frequency of exacerbations [2]. Since then, an improved
definition and classification of COPD exacerbations has
been introduced, along with several clinical trials of azi-
thromycin and a 2013 Cochrane review indicating a
significant reduction in the frequency of COPD exacer-
bations with prophylactic antibiotics [3–5].
Our study assessed the impact of twelve weeks of the
macrolide antibiotic roxithromycin (with and without
doxycycline) on exacerbation rate and lung function de-
cline in a COPD population with frequent exacerbations
prior to study entry. The study was originally designed
to test the hypothesis that Chlamydia pneumoniae (now
Chlamydophila pneumoniae) was a pathogenic factor in
the aetiology of COPD and that eradication of C. pneu-
moniae infection could reduce exacerbation rates [6, 7].
This hypothesis is now considered unsubstantiated and
is no longer believed to be clinically relevant [8–10].
Nevertheless, this study allowed us to address the role of
prophylactic antibiotics in reducing COPD exacerbations.
Results
Study participants
The screening, randomisation, withdrawals and proto-
col deviations are shown in the CONSORT diagram
(Fig. 1). Of the 717 patients initially assessed for eligi-
bility, 292 were randomised. Of the 425 excluded sub-
jects, 248 had negative C. pneumoniae serology with 77
subjects having fewer than three documented exacerba-
tions over the preceding two-year period. Table 1 com-
pares the characteristics of the 292 included and 425
excluded subjects. Apart from the known difference in
C. pneumoniae serological status, the major differences
were that the included cohort comprised a greater pro-
portion of men (73 % vs. 63 %), worse baseline forced
expiratory volume in 1 second (FEV1) (mean FEV1 pre-
dicted 34 % vs. 43 %) and a greater number of exacer-
bations (5.1 vs. 4.1 exacerbations within the previous
2 years) than the excluded cohort.
The baseline characteristics of the study participants
who were randomised are summarised in Table 2. The
roxithromycin/doxycycline combination group had more
current smokers than the other two groups (p < 0.001),
with no other statistically significant differences among
the treatment groups.
Primary outcome
COPD exacerbations over 48-week post-treatment period
The annualised moderate and severe event rates were
2.83 per patient year [95 % CI 2.37 – 3.40] in the roxithro-
mycin/doxycycline combination group, 2.69 per patient
year [95 % CI 2.26 – 3.21] in the roxithromycin only
group and 2.50 per patient year [95 % CI 2.08 – 3.03] in
the placebo group. There were no statistically significant
differences between either of the two active treatment
arms and the placebo group (p = 0.352 in the roxithromy-
cin/doxycycline group and p = 0.5832 in the roxithromy-
cin only group) (Table 3). Mean time to the first moderate
or severe event following active treatment period was
121 days (SD 113, 87 patients) in the roxithromycin/doxy-
cycline combination group, 140 days (SD 117, 92 patients)
in the roxithromycin only group and 147 days (SD 115, 87
patients) in the placebo group, with no statistically signifi-
cant difference among the groups (log logistic p = 0.254).
Secondary outcomes
COPD exacerbations over the 12-week treatment period,
and the first and last 24-week post-treatment periods
The exacerbation rate appeared slightly lower in the two
active treatment arms compared with the placebo group
during the active treatment period, however, this
Fig. 1 CONSORT diagram of the flow of participants. All randomised
participants were included in the analysis. The subjects who had
withdrawn from the study medication remained for the full assessment
period and were reviewed at the final visit day, as far as possible
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difference was not statistically significant (1.64 per pa-
tient year in the roxithromycin/doxycycline group and
1.74 per patient year in the roxithromycin only group
versus 2.25 per patient year in the placebo group, p =
0.1709 and p = 0.2545 respectively) (Table 3). There were
no statistically significant differences between either of
the two active treatments groups and the placebo group
in the annualized moderate and severe event rates over
either 24-week post-treatment period. When the analysis
was corrected for factors significantly associated with ex-
acerbation rate (age, weight, smoking status, FEV1 per-
centage predicted and the use of concomitant
antibiotics), there remained no statistically significant
difference among the groups.
FEV1 and Forced Vital Capacity (FVC) over 60-week period
By the end of the active treatment period (Fig. 2a), FEV1
increased by 5.5 % (47 mls) relative to baseline in the
roxithromycin/doxycycline group, 5.9 % (57 mls) in the
roxithromycin only group and 8.4 % (83 mls) in the pla-
cebo group. This remained more or less the same at
24 weeks and 48 weeks after treatment. These small im-
provements in FEV1 over the 60-week study period were
statistically significant in all groups (p < 0.0001). Overall
there was no significant difference among the treatment
groups at the end of the study (p = 0.278). With regard
to the change seen over time, there was no significant
difference among the treatment groups (p = 0.539). By
the end of the active treatment period (Fig. 2c), FVC in-
creased by 2.8 % (60 mls) relative to baseline in the roxi-
thromycin/doxycycline group, 3.9 % (90 mls) in the
roxithromycin only group and 1.9 % (43 mls) in the pla-
cebo group but these were not statistically significant (p =
0.3441), and overall there was no significant difference
among the treatment groups (p = 0.7192).
Chronic Respiratory Disease Questionnaire (CRQ) scores
over 60-week period
There were significant changes in the scores of all four
CRQ domains relative to baseline in each treatment
group over the 12-week active treatment and the 48-
week post-treatment period (Additional file 1: Table S1).
However there were no significant differences in any of
the four domains among the treatment groups, or in the
proportions of subjects meeting the minimum clinically
important difference.
Adverse events
Table S2 summarises the adverse events considered re-
lated to the study medication (Additional file 1: Table
S2). The most common adverse event was nausea in
both active treatment groups. There was only one case
of abnormal electrocardiogram (ECG) deemed related to
study medication in the roxithromycin/doxycycline
group. Most events were mild and no deaths were re-
lated to the study medication.
Discussion
The major finding of this study was the lack of effect on
the frequency of COPD exacerbations following a 12-
week treatment with roxithromycin either alone or in
combination with doxycycline in the COPD population
with serological evidence of previous C. pneumoniae in-
fection when compared with placebo. In addition there
was no significant difference among treatment groups
with regard to any of the other efficacy parameters ex-
amined i.e. lung function and quality of life scores.
At the time that this study was undertaken there was a
focus on the role of chronic infection with C. pneumo-
niae in the pathogenesis of chronic respiratory disorders
such as COPD. Subsequently, interest in C. pneumoniae
as an important cofactor in the aetiology of respiratory
diseases has dwindled [8, 10]. Previous studies have shown
that C. pneumoniae seropositivity is seen in up to 77 % of
stable COPD patients and is not significantly related to
FEV1 percentage predicted or exacerbation frequency
[9, 11]. Although the included cohort with positive C.
Table 1 Comparisons of baseline characteristics of the included
participants with the excluded participants
Included Excluded P-value
Number of patients 292 425 -
Age (year), mean (SD) 67.3 (8.58) 67.9 (9.5) 0.3564
Male, n (%) 214 (73.29 %) 268 (63 %) 0.005
Race, n (%)
New Zealand European 287 (98.29 %) 414 (97.6 %) 0.637
Maori/Pacific Islander 3 (1.03 %) 6 (1.4 %)
Other 2 (0.68 %) 4 (1 %)
Height (cm), mean (SD) 169.8 (8.6) 168 (8.8) 0.018
Weight (kg), mean (SD) 72.6 (16.5) 72.6 (16) 0.993
Smoking history, n (%)
Current smoker 71 (24.32 %) 116 (28 %) 0.272
Ex-smoker 221 (75.68 %) 298 (72 %)
Average tobacco consumption
(pack year), mean (SD)
56.58 (33.3) 53.7 (30) 0.355
Number of previous
exacerbations within
2 years, mean (SD)
5.11 (2.4) 4.15 (2.5) <0.0001
Spirometry
FEV1 (l), mean (SD) 0.935 (0.43) 1.17 (0.67) 0.0001
FEV1 (% predicted), mean (SD) 34 (14.8) 43.5 (23) <0.0001
FVC (l), mean (SD) 2.23 (0.83) 2.28 (0.93) 0.7983
FEV1/FVC mean (SD) 42 (10.2) 50 (14.8) <0.0001
Some data on spirometry and exacerbation rates in the excluded subjects
were missing
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pneumoniae serology had a greater degree of airflow ob-
struction and more exacerbations than the excluded pa-
tients, these findings are unlikely to have any impact on
the efficacy endpoints in this study or the interpretation of
these. Therefore it is plausible that the results of this clin-
ical trial might be generalised to other COPD patients
with frequent exacerbations.
The Cochrane review by Staykova et al published in
2003 analysed nine randomised controlled trials (all under-
taken prior to 1970) of prophylactic antibiotic therapy in
subjects with chronic bronchitis [2]. Tetracycline antibi-
otics predominated the clinical trials (including one trial
with tetracycline/macrolide combination) with a variable
treatment duration averaging 5 months. The 8.6 % reduc-
tion of exacerbations per patient year with treatment was
not statistically significant. There was no significant
reduction in exacerbation rate seen with tetracycline only
studies. The finding of the lack of effect of prophylactic
antibiotic use seen in our study is therefore in agreement
with the findings from these historical prophylactic
antibiotic studies.
Since this study was undertaken, a number of
prophylactic antibiotic trials have been undertaken
using newer macrolides and fluoroquinolones [4, 5,
12–17]. These studies followed the documented effi-
cacy of macrolide therapy in the cystic fibrosis (CF)
population and more recently in non-CF bronchiectasis
[18, 19]. Recent studies of azithromycin or erythromycin
in non-CF bronchiectasis showed that 6 to 12 month
treatment with these macrolides reduced the rate of exac-
erbations and prolonged the duration to first exacerba-
tions significantly [20–22].
Table 2 Baseline characteristics of participants by treatment groups
Roxithromycin/Doxycycline Roxithromycin alone Placebo
Number of patients 101 97 94
Age (year), mean (SD) 65.8 (7.9) 67.6 (7.85) 66.7 (8.7)
Male, n (%) 64 (63.37 %) 83 (85.57 %) 67 (71.28 %)
Race, n (%)
New Zealand European 99 (98.02 %) 96 (98.97 %) 92 (97.87 %)
Maori/Pacific Islander 1 (0.99 %) 1 (1.03 %) 1 (1.06 %)
Other 1 (0.99 %) 0 1 (1.06 %)
Height (cm), mean (SD) 168.6 (9.3) 171.4 (7.95) 169.5 (8.2)
Weight (kg), mean (SD) 70.85 (14.6) 72.8 (14.8) 74.5 (19.7)
Smoking history, n (%)
Current smoker 36 (35.64 %) 17 (17.53 %) 18 (19.15 %)
Ex-smoker 65 (64.36 %) 80 (82.47 %) 76 (80.85 %)
Average tobacco consumption (pack year), mean (SD) 57.96 (30.8) 54.36 (39) 57.38 (29.5)
Number of previous exacerbations within 2 years, mean (SD) 5.01 (2.34) 5.39 (2.56) 4.93 (2.29)
Spirometry
FEV1 (l), mean (SD) 0.85 (0.325) 0.965 (0.455) 0.99 (0.49)
FEV1 (% predicted), mean (SD) 32.53 (13.55) 33.93 (15.3) 35.8 (15.2)
FVC (l), mean (SD) 2.11 (0.78) 2.33 (0.82) 2.25 (0.9)
FEV1/FVC mean (SD) 41.54 (10) 41.5 (10.8) 43.7 (9.9)
CRQ
Dyspnoea, median (Min-Max) 15 (5 – 28) 15 (7 – 24) 16 (6 – 31)
Fatigue, median (Min-Max) 15 (5 – 25) 16 (5 – 26) 15 (5 – 26)
Emotional function, median (Min-Max) 33 (13 – 47) 33 (15 – 48) 32 (12 – 49)
Mastery, median (Min-Max) 21 (5 – 28) 21 (7 – 28) 19 (7 – 28)
Co-morbidity (n, %)
Ischaemic heart disease 6 (5.94 %) 11 (11.34 %) 13 (13.83 %)
Hypertension 36 (35.64 %) 39 (40.21 %) 33 (35.11 %)
Abnormal liver function 1 (0.99 %) 1 (1.03 %) 1 (1.06 %)
Gastroesophageal reflux disease 17 (16.83 %) 15 (15.46 %) 18 (19.15 %)
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In the updated Cochrane review on prophylactic anti-
biotic therapy in COPD, the largest randomised con-
trolled trial by Albert et al studied 12 months of once
daily 250 mg azithromycin in 1577 COPD patients [3,
5]. In accordance with our findings, there was no statis-
tically significant difference in COPD hospitalisations
(0.34 vs. 0.49 per patient year for azithromycin and pla-
cebo respectively), although the overall exacerbation rate
was lower in the active treatment group (1.48 vs. 1.83
per patient year) [5]. Unlike our study, half of the pa-
tients did not have history of frequent exacerbations,
hence the lower annualised exacerbation rates and lon-
ger duration to first exacerbation. A more recent trial by
Uzun et al used 500 mg azithromycin three times a week
for 12 months in a smaller cohort of 92 COPD patients
with history of three or more exacerbations in the
previous year [4]. The overall exacerbation rate was sig-
nificantly lower in the azithromycin group than placebo
(1.94 vs. 3.22 per patient year) as was the duration to
first exacerbation (130 vs. 59 days). However, the rates
of severe exacerbation and hospitalisation were not sta-
tistically different. They did not find any significant im-
provement in lung function and overall health-related
quality of life. Both of these one-year azithromycin trials
showed that the significant decrease in exacerbation
rates between the active and placebo groups was seen
within 3 months of treatment [4, 5]. Although we ob-
served a similar trend in our study, our results were not
statistically significant.
A more recent randomised controlled trial by Brill et
al of three different antibiotic regimens (including
azithromycin) in patients with stable COPD found that
Table 3 Moderate and severe exacerbations of COPD by treatment groups
Roxithromycin + Doxycycline (n = 101) Roxithromycin (n = 97) Placebo (n = 94)
Through 48-week period post treatment
Number of exacerbations N % of overall exacerbations N % of overall exacerbations N % of overall exacerbations
Overall 263 302 261
Moderate and severe 217 82.51 % 221 73.18 % 193 73.94 %
Event rate/patient year
Overall 3.43 3.67 3.38
Moderate and severe 2.83 aP = 0.352 2.69 aP = 0.5832 2.50
During 12-week active treatment period
Number of exacerbations N % of overall exacerbations N % of overall exacerbations N % of overall exacerbations
Overall 52 51 67
Moderate and severe 37 71.15 % 39 76.47 % 48 71.64 %
Event rate/patient year
Overall 2.31 2.27 3.14
Moderate and severe 1.64 aP = 0.1709 1.74 aP = 0.2545 2.25
During the first 24-week period post treatment
Number of exacerbations N % of overall exacerbations N % of overall exacerbations N % of overall exacerbations
Overall 146 150 141
Moderate and severe 117 80.13 % 108 72 % 103 73.05 %
Event rate/patient year
Overall 3.72 3.57 3.55
Moderate and severe 2.98 aP = 0.3864 2.57 aP = 0.9577 2.59
During the last 24 week period post treatment
Number of exacerbations N % of overall exacerbations N % of overall exacerbations N % of overall exacerbations
Overall 117 152 120
Moderate and severe 100 85.47 % 113 74.34 % 90 75 %
Event rate/patient year
Overall 3.12 3.78 3.20
Moderate and severe 2.67 aP = 0.5426 2.81 aP = 0.3496 2.40
Number and event rate (per patient year) of moderate and severe exacerbations in each treatment group. aP values shown are from comparison of event rate
with the placebo group
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there was no significant reduction in sputum bacterial
load following 3 months of treatment [23]. This suggests
that azithromycin’s action in reducing the risk of exacer-
bations in COPD patients may be due to its immuno-
modulatory effect as suggested by previous authors [24].
Even though the number of patients who did not wish
to continue on the study medications was higher in the
roxithromycin/doxycyline group than the roxithromycin
and placebo groups, their decisions were not related to
the adverse events. We found that the adverse events
from prophylactic antibiotics were tolerable and apart
from nausea, were comparable between the treatment
groups. Macrolides, however, are known to have cardiac
side effects (e.g. prolonged QT interval) and could po-
tentially cause malignant arrhythmia, such as torsades
des pointes. A retrospective study on azithromycin by
Ray et al showed that its use was associated with increased
cardiovascular deaths [25]. Erythromycin and azithromy-
cin are also potent inducers of antimicrobial resistance in
both non-CF bronchiectasis and COPD studies [5, 20, 21].
Herath et al, although unable to analyse the development
of antibiotic resistance in their review, conveyed their con-
cern on the impact of bacterial macrolide resistance as ob-
served in the study by Albert et al. [3 5]. The more recent
trials by Uzun et al and Brill et al have also shown the de-
velopment of antimicrobial resistance [4, 23]. This resist-
ance may limit treatment options for acute bacterial
respiratory infection and even increase respiratory mortal-
ity. Our study in which antibiotics were given for twelve
weeks did not examine antimicrobial resistance.
One of the strengths of our study is that it looked at
both the 12-week on-treatment period and the 48-week
run-out period, in order to see if any sustainable impact
was present beyond the treatment period. Another is that
even though the number of patients recruited did not
reach the target, the dropout rate was lower than expected
and therefore the number of patients was adequate in
order to achieve statistical significance. This is one of the
largest double-blind placebo-controlled trials undertaken
on antibiotic prophylaxis in COPD in recent years.
This study has several limitations. There was a delay
in getting the study prepared for publication. This was
due a combination of factors which included the un-
timely death of the principal investigator. However, there
was no delay in the analysis of the data and the results
remained valid throughout this period. Although the
study only included participants seropositive to C. pneu-
monia, as discussed above, our study cohort is likely to
be representative of COPD patients with a history of fre-
quent exacerbations. The duration of antibiotic therapy
of twelve weeks is shorter than other studies [3–5], which
could limit any possible antimicrobial and anti-
inflammatory effects of these antibiotics.
Conclusions
Twelve weeks of treatment with roxithromycin alone or
in combination with doxycycline was tolerable but did
not reduce the frequency of exacerbations in patients
with COPD either during the treatment period or in the
subsequent 48 weeks. The outcome of this study cer-
tainly does not justify the use of these antibiotics to pre-
vent COPD exacerbations. There remains the need for a
more targeted approach to reduce exacerbations in
COPD patients with frequent exacerbations than the use
of prophylactic antibiotics.
Methods
This study was undertaken between February 2000 and
April 2002 in 16 centres across Australia and New
Fig. 2 Time-course of spirometry by treatment groups. Trend from
baseline to week 12 (end of treatment), week 36 and week 60 (end
of follow up period) for a) mean absolute FEV1, b) FEV1 percentage
predicted, c) mean absolute FVC and d) FEV1/FVC, by treatment groups
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Zealand. It was designed specifically to look at the role
of antibiotic therapy active against Chlamydia pneu-
moniae in a COPD population with serological evi-
dence of previous C. pneumoniae infection. The study
endpoints and the statistical analysis (apart from those
in relation to C. pneumoniae), and the sample size cal-
culation were as per the originally designed study protocol
(Additional file 2).
Study participants
The inclusion criteria were subjects aged 45 years or older,
meeting spirometric criteria for COPD (FEV1 ≤ 70 % pre-
dicted, ratio of FEV1 over FVC (FEV1/FVC) ≤ 60 %, revers-
ibility of ≤ 10 % of predicted FEV1 or ≤ 200 ml if predicted
FEV1 ≤ 2 L); smoking history ≥ 20 pack years; and at least
three confirmed moderate or severe COPD exacerbations
in the past two years (i.e. requiring treatment with antibi-
otics and/or oral corticosteroids and/or hospitalisation). In
view of the original hypothesis, an additional inclusion cri-
terion was positive serology for C. pneumoniae (IgG anti-
body titre ≥1:64).
The exclusion criteria were pulmonary disease other
than COPD; treatment with antibiotics, exacerbation or
an investigational drug in the four weeks before ran-
domisation; pregnancy (serum pregnancy test) or breast
feeding; history of hypersensitivity to macrolides, tetracy-
clines, beta-lactams or sulfamethoxazole:trimethoprim;
serious cardiovascular, hepatic, renal or other systemic dis-
eases; known long QT syndrome or corrected QT interval
(QTc) >450 ms, sick sinus syndrome, bradycardia (<50
beats per minute) or severe hypokalaemia; epilepsy; treat-
ment with medicine known to have important interaction
with macrolides or tetracyclines; impaired hepatic function
(aspartate aminotransferase or alanine aminotransferase ≥
2 times of the upper limit of normal (ULN), alkaline phos-
phatase ≥ 1.25 times the ULN, bilirubin >2 times the ULN
and albumin <30 g/L); or unlikely to comply.
Written informed consent was obtained from each
subject prior to enrolment in the study. Ethics approval
was obtained from the local ethics committees of each
of the participating sites. This trial was retrospectively
registered with the Australian New Zealand Clinical
Trials Registry (ANZCTRN12615000052538).
Interventions
This randomised placebo-controlled double-blind double-
dummy parallel group study compared three different
treatments administered over a three month period: 1) the
macrolide roxithromycin 300 mg alone; 2) the combin-
ation of roxithromycin 300 mg daily and the tetracycline
antibiotic doxycycline 100 mg daily; or 3) matching pla-
cebo. Based on the original hypothesis, the combination
of roxithromycin and doxycycline would be more effective
in eradicating C. pneumoniae than roxithromycin alone
and would lead to decreased exacerbation rates and im-
proved lung function [26, 27].
Hoechst Marion Roussel and Douglas Pharmaceuticals
manufactured roxithromycin and doxycycline tablets re-
spectively, together with their identical placebo tablets.
Study medication was packed by Hoechst Marion Rous-
sel in bottles labelled with the randomisation and batch
numbers. The investigators, pharmacists and subjects
were blinded to the study medication in these bottles.
After a 2-week run-in period, each eligible patient was
assigned a sequential subject number followed by ran-
domisation number provided by Hoechst Marion Roussel,
Australia. Subjects were supplied with one of the three
treatments according to their randomisation number.
After completing the initial 12-week antibiotic period, par-
ticipants were followed up for a further 48 weeks, for a
total of 60 weeks.
Outcome variables
The primary outcome variable was the frequency of
moderate and severe exacerbations (defined below) over
the 48-week post treatment period. The secondary out-
come variables were the number of exacerbations of
COPD over the active treatment period, and the first
and last 24-week periods after treatment; spirometric
volume changes (FEV1 and FVC); Chronic Respiratory
Disease Questionnaire (CRQ) scores, and adverse events
over the 60-week period. Minimum clinically relevant
changes for each domain of the CRQ scores were de-
fined as a change of 3 points for dyspnoea, 4 points for
emotional function, 2 points for fatigue and mastery (as
per Guyatt) [28, 29].
An acute exacerbation was defined by either at least 2
out of 3 of the following, on 3 consecutive days or more,
change in sputum production; change in sputum puru-
lence; and change in breathlessness; or diagnosed and
treated by the investigator based on clinical symptoms.
Exacerbation severity was defined as ‘mild’ if it was self-
managed by the patient at home (e.g. increase in bron-
chodilator and/or non-prescription medication use);
‘moderate’ if it required treatment with antibiotics and/
or an increase in dose of, or initiation of corticosteroids
by a medical practitioner; or ‘severe’ if it resulted in hos-
pitalisation or death due to an exacerbation of COPD.
Data collection
A full medical history was obtained at the screening
visit. A full physical examination was performed at ran-
domisation and at the end of treatment. CRQ and spirom-
etry (performed according to the European Respiratory
Society guidelines) were done at week 0, 12, 36 and 60. A
12-lead ECG was performed on all patients at randomisa-
tion, during treatment and at the end of treatment. QTc
was calculated using Bazett’s formula. Any adverse events
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observed by the investigator or reported by the subject
were documented. Details of any exacerbations, changes
in medication, and adverse events were collected from the
Daily Diary Cards provided to each subject and from
regular telephone assessments. All subjects were ad-
vised to contact site investigators if they were experi-
encing any exacerbations for details of symptoms, and
information on doctor visits or hospitalisations. Spu-
tum microbiology and antimicrobial resistance were
not incorporated into this study.
Statistical analysis
Comparison of baseline characteristics was done using
the chi-squared test, student’s t-test or Wilcoxon rank-
sum test. Comparison of event rates (number of events/
exposure patient days) among the three treatment arms
was done using a Poisson model. Analysis of variance
models were used to test for differences in numbers of
exacerbations among the three treatment groups. Statis-
tical analyses for all secondary outcome variables were
performed at the end of the 60-week study period in
comparison with baseline values. Analysis of time to first
moderate or severe exacerbations was performed using
log-logistic distribution model. CRQ scores were ana-
lysed using autoregressive models and likelihood-ratio
tests. All randomised patients were included in the
intention-to-treat analyses. The subjects who had with-
drawn from the study medication remained for the full
assessment period and were reviewed at the final visit
day, as far as possible. Data were entered and managed
in a Clintrial database. The SAS statistical package was
used for all analyses. There was no delay in the analyses
of data for the study endpoints and they were performed
right after completion of the study.
Sample size justification
The mean number of moderate and severe exacerbations
per year was estimated to be 2.5 (SD 1) in each group.
An analysis of variance-based F-test would require 83
subjects in each treatment group to have 90 % power to
detect a difference in the exacerbation rate of 0.5 per
year at the 5 % significance level. Thus a total of 249
subjects would be required. If a dropout rate were
approximately 20 %, 312 subjects would be required.
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Additional file 1: Table S1. Chronic Respiratory Questionnaire (CRQ)
scores by treatment groups, and Table S2 Adverse events by treatment
groups. (DOCX 85 kb)
Additional file 2: Study Protocol. (PDF 2741 kb)
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